Dna Methylation Episignatures are Sensitive and Specific Biomarkers for Detection of Patients with Kat6A / Kat6B Variants
Epigenomics · 2023-03 · 15 (6) · 351-367
DOI: 10.2217/epi-2023-0079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomics, online erschienen am 30.05.2023. Verfasst von Niels Vos und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: DNA Methylation, Neurodevelopmental Disorders. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Ontario Genomics Institute.
Abstract (Originalsprache)
Accurate diagnosis for patients living with neurodevelopmental disorders is often met with numerous challenges, related to the ambiguity of findings and lack of specificity in genetic variants leading to pathology. Genome-wide DNA methylation analysis has been used to develop highly sensitive and specific 'episignatures' as biomarkers capable of differentiating and classifying complex neurodevelopmental disorders. In this study we describe distinct episignatures for KAT6A syndrome, caused by pathogenic variants in the lysine acetyltransferase A gene (KAT6A), and for the two neurodevelopmental disorders associated with lysine acetyl transferase B (KAT6B). We demonstrate the ability of our models to differentiate between highly overlapping episignatures, increasing the ability to effectively identify and diagnose these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
- Department of Pathology & Laboratory Medicine, Western University, London, ON, N6A 5C1, Canada.
- Department of Pediatrics, Sainte-Justine UHC & University of Montreal, Montreal, QC, H3T 1C5, Canada.
- Department of Metabolic Medicine, Queensland Children's Hospital, South Brisbane, QLD 4101, Australia.
- School of Medicine, University of Queensland, Brisbane, QLD 4072, Australia.
- Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Victoria, 3052, Australia.
ORCID-Profile: Jack Reilly, Marcel Mannens, Bekim Sadikovic
Förderung
- Ontario Genomics Institute
Zitieren
APA
Vos, N., Reilly, J., Elting, M. W., Campeau, P. M., Coman, D., Stark, Z., Tan, T. Y., Amor, D. J., Kaur, S., StJohn, M., Morgan, A. T., Kamien, B. A., Patel, C., Tedder, M. L., Merla, G., Prontera, P., Castori, M., Muru, K., Collins, F., …, & Sadikovic, B. (2023). Dna Methylation Episignatures are Sensitive and Specific Biomarkers for Detection of Patients with Kat6A / Kat6B Variants. Epigenomics, 15(6), 351-367. https://doi.org/10.2217/epi-2023-0079
Vancouver
Vos N, Reilly J, Elting MW, Campeau PM, Coman D, Stark Z, et al. Dna Methylation Episignatures are Sensitive and Specific Biomarkers for Detection of Patients with Kat6A / Kat6B Variants. Epigenomics. 2023;15(6):351-367. doi:10.2217/epi-2023-0079
BibTeX
@article{Vos2023,
author = {Vos, Niels and Reilly, Jack and Elting, Mariet W and Campeau, Philippe M and Coman, David and Stark, Zornitza and Tan, Tiong Yang and Amor, David J and Kaur, Simran and StJohn, Miya and Morgan, Angela T and Kamien, Benjamin A and Patel, Chirag and Tedder, Matthew L and Merla, Giuseppe and Prontera, Paolo and Castori, Marco and Muru, Kai and Collins, Felicity and Christodoulou, John and Smith, Janine and Zeev, Bruria Ben and Murgia, Alessandra and Leonardi, Emanuela and Esber, Natacha and Martinez-Monseny, Antonio and Casas-Alba, Didac and Wallis, Matthew and Mannens, Marcel and Levy, Michael A and Relator, Raissa and Alders, Marielle and Sadikovic, Bekim},
title = {Dna Methylation Episignatures are Sensitive and Specific Biomarkers for Detection of Patients with Kat6A / Kat6B Variants},
journal = {Epigenomics},
year = {2023},
volume = {15},
number = {6},
pages = {351--367},
doi = {10.2217/epi-2023-0079}
}
EUVIMED